ASLAN Pharma will host its first R&D day in Taipei, Taiwan, on 29 November 2017.
Taipei, Taiwan, 28 November 2017 – ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, will host its first R&D day in Taipei, Taiwan, on 29 November 2017.
Members of ASLAN’s senior management, with key opinion leaders and industry experts, will provide an overview of ASLAN’s pipeline of novel drugs, along with updates on their progress and clinical status.
Speakers include:
• Dr Cheng-Hsu Wang, Chairman, HOPE Foundation for Cancer Care
•Dr Matthew Ng, Senior Consultant, National Cancer Centre Singapore
• Dr Chin Hin Ng, Consultant, National University Cancer Institute Singapore
• Dr Carl Firth, Chairman & CEO, ASLAN Pharmaceuticals
• Dr Mark McHale, Chief Operating Officer, ASLAN Pharmaceuticals
• Dr Bertil Lindmark, Chief Medical Officer, ASLAN Pharmaceuticals
• Dr Chih-Yih Hsieh, Vice President (Medical) and General Manager (Taiwan), ASLAN Pharmaceuticals
No new company information will be shared at this event.
The event is open to analysts, institutional investors and members of the media. For more information, please email Wendy.Kao@aslanpharma.com.
